Clinical Reasoning: A 39-Year-Old Man With Asymmetric Distal Weakness and Loss of Sensitivity

Author(s):
Valentin Loser, MD¹; Gabriela Blanchard, MD²; Emmanuella Guenova, MD²; Marie Théaudin, MD¹; Alex Vicino, MD¹

Corresponding Author:
Valentin Loser, valentin.loser@chuv.ch

Affiliation Information for All Authors: 1. Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; 2. Dermatology Service, Lausanne University Hospital and University of Lausanne

Equal Author Contribution:

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Copyright © 2022 American Academy of Neurology. Unauthorized reproduction of this article is prohibited
Contributions:
Valentin Loser: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Gabriela Blanchard: Drafting/revision of the manuscript for content, including medical writing for content
Emmanuella Guenova: Drafting/revision of the manuscript for content, including medical writing for content
Marie Théaudin: Drafting/revision of the manuscript for content, including medical writing for content
Alex Vicino: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Figure Count:
1

Table Count:
1

Search Terms:

Acknowledgment:

Study Funding:
The authors report no targeted funding

Disclosures:
The authors report no disclosures relevant to the manuscript.

Preprint DOI:

Received Date:
2022-05-13

Accepted Date:
2022-08-30
Abstract

A 39-year-old man presented with an asymmetric distal weakness and loss of sensitivity sequentially affecting both lower extremities and the left upper limb. Nerve conduction studies showed a multifocal sensory and motor axonal neuropathy, and a pseudo-conduction block of the right fibular nerve, the whole being consistent with a mononeuropathy multiplex. An uncommon etiology was found after an extensive workup. Axonal loss was severe, with only partial response to treatment with corticosteroids and intravenous immunoglobulins.

Section 1

A 39-year-old man developed transient fever, headache and night sweats. After two weeks, he experienced sensory loss in the left leg and dorsal foot upon awakening. A few hours later, the sensory deficit extended to the sole of the left foot and the following day, he had the same symptoms in the right foot. Two days later, he rapidly developed weakness of left foot plantar flexion, and three days later, of right foot dorsiflexion. The symptoms were initially painless, but he secondarily developed severe neuropathic pain of both lower extremities. At this time, he did not have any additional symptoms suggestive of systemic involvement. He then presented to the emergency department.

At admission, nine days after symptoms onset, vital parameters were within normal limits. General examination showed slightly painful erythematous papules and nodules on the front of both legs. On neurological examination, there was severe paresis of right foot dorsiflexion (MRC 2) and eversion (MRC 3), left foot flexion and inversion (MRC 4). Left Achilles reflex was absent. Plantar responses were in flexion. There was decreased sensation to touch and pain in both superficial fibular territories and anesthesia in the left plantar nerve territory.

Initial workup disclosed a discrete inflammatory syndrome (erythrocyte sedimentation rate 35 mm/h, C-reactive protein <5 mg/l) and a normocytic normochromic anemia.

Questions for consideration:

1. Where do you localize the affection in the nervous system?
2. What diagnostic test would you first perform?

Section 2

Sensory and motor impairment in both lower limbs may suggest a myelopathy. However, the absence of upper motor neuron signs and sphincter disturbance rather suggest a peripheral neuropathy.

Nerve conduction studies (NCS) performed nine days after symptoms onset showed an asymmetric peripheral neuropathy, with a motor conduction block in the right fibular nerve above the fibular head (Figure 1A) and a reduced amplitude of the left sural and superficial fibular sensory nerve action potentials (SNAPs). Other studied nerves were normal (eTable 1, in the supplement).
Questions for Consideration

1. What is the most likely syndromic diagnosis?
2. What additional test would you perform to confirm diagnosis?

Section 3

The disease presented with rapidly progressing, asymmetric, multiple trunk sensory-motor nerve involvement. NCS showed a multifocal sensory and motor axonal neuropathy, suggestive of mononeuropathy multiplex. The differential diagnosis included the multifocal variant of inflammatory demyelinating polyradiculoneuropathy. However, the onset of symptoms within a few days and the axonal neuropathy pattern refute this hypothesis.

Conduction block describes the physiologic phenomenon in which saltatory conduction is blocked at a point of the nerve, and is defined as a loss of amplitude/area of the compound motor action potential (CMAP) on proximal stimulation compared to distal stimulation. The amplitude/area reduction has to range from 20 to 50%, depending on the set of criteria used. 1 Usually, conduction block is a sign of focal demyelination, which can be seen in inflammatory demyelinating neuropathies, like Guillain-Barré syndrome, or be a consequence of focal ion channels dysfunction in nodo-paranodopathies. In the event of a recent axonal interruption, such as nerve trauma or ischemic damage, a transient conduction block may be observed during the first few days following the lesion. Indeed, the distal extremities of the nerves remain capable of conducting impulses for a few days before Wallerian degeneration process is completed. The conduction block is therefore transient (“pseudo-conduction block”) and will later give way to a decrease in the amplitude of the distal CMAP response. 2

Mononeuropathy multiplex, especially when associated to pain and systemic involvement should suggest a vasculitic process. We therefore performed a skin biopsy of the pre-tibial lesions, which showed a small and medium-sized vessels necrotizing vasculitis, including fibrinoid necrosis of the vascular wall (Figure 1 C-F).

Questions for Consideration

1. What are the most common etiologies of mononeuropathy multiplex?
2. What diagnostic tests would you perform?

Section 4

In most cases, mononeuropathy multiplex is one of the manifestations of a primary systemic vasculitis, affecting small or medium-sized vessels, including polyarteritis nodosa, ANCA-associated vasculitis and cryoglobulinemic vasculitis. Vasculitis can also be secondary to a systemic immunologic disease, an infection, some drugs or malignancy (Table 1). Finally, it can only affect the peripheral nervous system, without an obvious trigger, which is defined as a non-systemic vasculitic neuropathy. 3

The workup should include a broad immunological blood work, including ANA, ANCA, rheumatoid factor, antinucleoprotein and cryoglobulins, and an infectious screening, including HIV, syphilis, Lyme and hepatitis B, C and E viruses serologies. A more thorough infectious workup may be performed.
depending on the exposure. If systemic vasculitis is suspected, chest and abdomen CT is also indicated to look for systemic involvement.

In our patient, immunological assessment, including ANA, ANCA and cryoglobulins, was negative. Cerebrospinal fluid examination did not show any abnormality. Chest and abdomen CT showed multiple pulmonary nodules and micronodules, and mesenteric and retroperitoneal lymph nodes. Infectious tests were negative, apart from a positive parvovirus B19 serology (IgG index 35, norm <1.1 and IgM index 1.9 norm <1.1). We performed a biopsy of the right peroneus brevis muscle which was within normal limits. A polymerase chain reaction (PCR) for parvovirus B19 was positive in the muscle sample, but negative in the skin biopsy, which could be related to patchy vasculitis involvement.

We therefore made a diagnosis of possible parvovirus B19 associated small- and medium-sized vessels necrotizing vasculitis.

Questions for Consideration

1. How would you treat the patient?

Section 5

The general principle of treatment of vasculitic neuropathy is the rapid introduction of immunosuppressive therapy, to prevent further nerve damage. The standard initial therapy is high-dose corticosteroid, usually by prednisone (1.0 mg/kg/d), which may be preceded in severe cases by intravenous methylprednisolone (500-1000 mg/d for 3-5 days). The introduction of maintenance immunosuppressive therapy then depends on the etiological diagnosis.

Twelve days after symptoms onset, we introduced a course of IV methylprednisolone (500 mg/d) for 3 days, with oral prednisone relay (1 mg/kg/d). During the first 3 days of treatment, the patient kept clinically worsening, with complete paresis of right foot dorsiflexion. Five days after corticosteroid initiation, he developed a left proximal sensory-motor median neuropathy. Hence, treatment with intravenous immunoglobulin (IVIg) was immediately introduced (2g/kg over 5 days). A few days after IVIg initiation, there was already an improvement of the sensory-motor symptoms of the left upper limb and a slight improvement of the sensory symptoms in the lower limbs. Motor impairment in lower limbs did not progress further. The patient was then discharged home with a tapering prednisone therapy.

At follow-up, one month after discharge, the patient reported a slight improvement of the sensory symptoms of the lower extremities, but persistence of important motor disability. On neurological examination, he had severe paresis of right foot and hallux dorsiflexion (M1) and eversion (M2), mild paresis of left foot flexion, inversion and hallux dorsiflexion (M4+) and severe paresis of left hallux flexion (M1). There was hypoesthesia of left median nerve territory, of both superficial fibular nerve territories and anesthesia of left plantar nerve territory. NCS showed diffuse new axonal loss of several nerves, with abolition of right fibular (Figure 1B) and left tibial nerve CMAP, reduction of left fibular and median nerve and right tibial nerve CMAP amplitude, reduction of the left median and right sural nerve SNAP amplitude and an abolition of the left sural and both superficial fibular SNAPs (eTable 1).
Discussion

Here we report a case of small and medium sized vessel necrotizing vasculitis characterized by mononeuropathy multiplex, skin, and systemic involvement, probably associated with an acute parvovirus-B19 infection. Treatment with corticosteroids was ineffective, and treatment with one cycle of IVIg 2g/kg allowed a partial improvement. The nerve damage was severe, as evidenced by the significant axonal loss displayed by follow-up NCS. We performed a third NCS three months after discharge, which did not display any progression of the axonal loss. Thus, IVIg treatment probably stopped the underlying vasculitic mechanism and stabilized the axonal neuropathy, nevertheless leaving motor sequelae secondary to the initial axonal damage.

Mononeuropathy multiplex is generally the consequence of a vasculitic phenomenon, producing an inflammation of the small caliber vessels wall involved in nerve vascularization (vasa nervorum) and leading to ischemia and infarction of the nerve. Nerve vasculitis can be proven histologically by a nerve-muscle biopsy, usually the sural or superficial peroneal nerve, with a sensitivity between 50 and 60%. If a diagnosis of systemic vasculitis that included a biopsy of another involved organ is established, nerve biopsy can be avoided.

Several viruses have been implicated in mononeuropathy multiplex, either by a direct cytopathic mechanism, or an indirect autoimmune response. Parvovirus B19 infection has been reported in some patients with necrotizing vasculitis, and has been involved in several central and peripheral nervous system complications including some cases of mononeuropathy multiplex.

The diagnosis of mononeuropathy multiplex is clinical; NCS are useful in confirming the multifocal axonal neuropathy. The presence of “pseudo-conduction block” has been described in this pathology.

Mononeuropathy multiplex is a neurological emergency, the vasculitic mechanism at its origin often leading to irreversible ischemia and necrosis of the affected nerve. The introduction of immunotherapy, especially high-dose corticosteroids, should therefore be done immediately upon suspicion. Parvovirus B19 associated vasculitis with mononeuropathy multiplex appears to respond poorly to corticosteroids but pretty well to treatment with IVIg, which may suggest an antiviral mechanism of IVIg in addition to the expected delayed immunomodulatory effect.
Figures and Tables

**Figure 1** Nerve conduction study and skin biopsy of a left pretibial erythematous lesion

**Figure 1 legend:** (A-B) Right fibular nerve motor conduction study performed 9 days (A) and 52 days (B) after symptom onset. Presence of a conduction block above the fibular head. CMAP amplitude at the ankle (A1) is 5.3 mA, at the fibular head (A2) is 4.3 mA and at the knee (A3) is 0.5 mA. Loss of amplitude between knee and ankle is 90.6% and loss of surface is 90.2%. At 52 days follow-up (B), no right fibular CMAP recordable at the ankle, suggestive of severe axonal loss secondary to Wallerian degeneration. (C-F) Hematoxylin and eosin (H&E) staining of the skin biopsy shows superficial and deep dermal and subcutaneous infiltration with neutrophils and disruption of small- and medium-sized blood vessels walls (black arrows, figure C, D) with leucocytoclasia (black arrows, figure E) and fibrinoid necrosis (black arrows, figure F). EDB = *Extensor digitorum brevis*. NR = No response.
Table 1 Most common etiologies of vasculitic neuropathies

Table 1 legend: Adapted with permission from Wolters Kluwer Health, Inc.: Karam C. Peripheral Neuropathies Associated With Vasculitis and Autoimmune Connective Tissue Disease. Continuum (Minneap Minn). 2020;26(5):1257-1279.

| Primary systemic vasculitides | ANCA-associated vasculitis:  
|                              | - Microscopic polyangiitis  
|                              | - Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome)  
|                              | - Granulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis)  
|                              | Essential mixed cryoglobulinemia  
|                              | Polyarteritis nodosa  
| Secondary systemic vasculitides | Connective tissue diseases:  
|                              | - Rheumatoid arthritis  
|                              | - Systemic lupus erythematosus  
|                              | - Sjögren syndrome  
|                              | - Systemic sclerosis  
|                              | - Mixed connective tissue disease  
|                              | - Dermatomyositis  
| Other systemic diseases:  
|                              | - Sarcoidosis  
|                              | - Behçet disease  
|                              | - Inflammatory bowel disease  
| Infections:  
|                              | - Hepatitis B, C and E virus, CMV, EBV, HSV, HIV, HTLV-1, parvovirus B19  
|                              | - Leprosy  
|                              | - Lyme disease  
| Drugs  
| Malignancy  
| Non-systemic vasculitic neuropathy | Including:  
|                              | - Postsurgical inflammatory neuropathy  
|                              | - Wartenberg migratory sensory neuropathy  
|                              | - Diabetic radiculoplexus neuropathy  

WNL-2022-201289_etab1 --- http://links.lww.com/WNL/C438
References

Clinical Reasoning: A 39-Year-Old Man With Asymmetric Distal Weakness and Loss of Sensitivity
Valentin Loser, Gabriela Blanchard, Emmanuella Guenova, et al.
Neurology published online October 18, 2022
DOI 10.1212/WNL.0000000000201410

This information is current as of October 18, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2022/10/18/WNL.0000000000201410.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
EMG
http://n.neurology.org/cgi/collection/emg
Peripheral neuropathy
http://n.neurology.org/cgi/collection/peripheral_neuropathy
Vasculitis
http://n.neurology.org/cgi/collection/vasculitis
Viral infections
http://n.neurology.org/cgi/collection/viral_infections

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise